SCHEMBL5040905

SCHEMBL5040905

COc1ccc(C(OC)C(=O)NCc2ccc(C(=N)NO)cc2)c(O)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HDAC1 Q13547 5/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM1A O60341 2/20 0.41
APP P05067 1/20 0.41
KMT2A Q03164 2/20 0.40
ANPEP P15144 1/20 0.40
TSHR P16473 1/20 0.39
F2 P00734 1/20 0.39
MEN1 O00255 1/20 0.39
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040912 1.00 ALDH1A1 (0.41) ALDH1A1HDAC1HDAC6NPC1RAB9A
SCHEMBL5041230 0.89 L3MBTL1 (0.41) ALDH1A1HDAC1HDAC6NPC1RAB9A
SCHEMBL5041225 0.89 L3MBTL1 (0.41) ALDH1A1HDAC1HDAC6NPC1RAB9A
SCHEMBL5042010 0.88 F2 (0.50) ALDH1A1NPC1RAB9APKMSMN1; SMN2
SCHEMBL5042016 0.88 F2 (0.50) ALDH1A1NPC1RAB9APKMSMN1; SMN2
SCHEMBL5041986 0.81 GSK3B (0.44) ALDH1A1RAB9APKMKMT2ATSHR
SCHEMBL5041980 0.81 GSK3B (0.44) ALDH1A1RAB9APKMKMT2ATSHR
SCHEMBL5041334 0.80 MAPK1 (0.40) ALDH1A1HDAC1HDAC6NPC1RAB9A
SCHEMBL5041340 0.80 MAPK1 (0.40) ALDH1A1HDAC1HDAC6NPC1RAB9A
SCHEMBL5042056 0.77 F2 (0.49) ALDH1A1NPC1RAB9APKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US claimed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US claimed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 ALDH1A1 519/4885HDAC1 3142/4885HDAC6 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.